Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Hillevax Inc (HLVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HLVX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.46% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 104.26M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 2 | Beta 0.77 | 52 Weeks Range 1.34 - 2.17 | Updated Date 08/15/2025 |
52 Weeks Range 1.34 - 2.17 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.29 | Actual -0.23 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.48% | Return on Equity (TTM) -40.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31743875 | Price to Sales(TTM) - |
Enterprise Value -31743875 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.07 | Shares Outstanding 50125500 | Shares Floating 27408113 |
Shares Outstanding 50125500 | Shares Floating 27408113 | ||
Percent Insiders 17.09 | Percent Institutions 72.02 |
Upturn AI SWOT
Hillevax Inc
Company Overview
History and Background
Hillevax Inc, founded in 2012, is a biopharmaceutical company focused on developing and commercializing novel vaccines for global health. It achieved significant milestones by advancing its norovirus vaccine candidate, HIL-214, through clinical trials.
Core Business Areas
- Vaccine Development: Focuses on researching, developing, and manufacturing vaccines against infectious diseases, primarily norovirus.
- Clinical Trials: Conducting and managing clinical trials to assess the safety and efficacy of vaccine candidates.
- Commercialization: Planning and executing the commercial launch of approved vaccines.
Leadership and Structure
The leadership team includes experienced executives in vaccine development and commercialization. The organizational structure consists of research, clinical development, manufacturing, and commercial operations departments.
Top Products and Market Share
Key Offerings
- HIL-214 (Norovirus Vaccine Candidate): HIL-214 is Hillevax's lead vaccine candidate targeting norovirus. The market share is currently 0% as it's not yet commercialized. Key competitors include Takeda Pharmaceutical Company Limited (TAK) with its norovirus vaccine program. Revenue is $0 as it is in development stages.
Market Dynamics
Industry Overview
The vaccine market is experiencing growth driven by increasing awareness of preventative healthcare and technological advancements in vaccine development. The norovirus vaccine market is an emerging market.
Positioning
Hillevax is positioning itself as a leader in norovirus vaccine development, aiming to address a significant unmet medical need with its HIL-214 candidate.
Total Addressable Market (TAM)
The total addressable market for norovirus vaccines is estimated to be in the billions of USD annually, driven by the high incidence of norovirus infections globally. Hillevax is positioned to capture a significant portion of this TAM pending successful commercialization of HIL-214.
Upturn SWOT Analysis
Strengths
- Focus on norovirus vaccine development
- Experienced leadership team
- Advanced clinical trial stage for HIL-214
Weaknesses
- Reliance on a single product candidate
- Limited commercialization experience
- Dependence on successful clinical trial outcomes
Opportunities
- Partnerships with pharmaceutical companies
- Expansion to other vaccine targets
- Global market expansion
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- TAK
Competitive Landscape
Hillevax faces competition from larger pharmaceutical companies with greater resources and established vaccine portfolios. Hillevax's advantage lies in its specialized focus on norovirus.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in clinical trials and funding secured.
Future Projections: Future growth is projected based on successful commercialization of HIL-214 and expansion of the vaccine pipeline.
Recent Initiatives: Recent initiatives include advancing HIL-214 through Phase 3 clinical trials.
Summary
Hillevax is a development-stage company focused on norovirus vaccines and holds a lead position in the market. It relies heavily on the success of its lead candidate HIL-214. Significant risks include clinical trial failures, competition, and regulatory hurdles. The company's future hinges on the ability to successfully commercialize its vaccine.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hillevax Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-04-29 | Co-Founder, President, CEO & Chairman of the Board Dr. Robert M. Hershberg M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.hillevax.com |
Full time employees 14 | Website https://www.hillevax.com | ||
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.